Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Herrlinger

Showing results (151-160 of 243) with videos related to

Pageof 25
Sort By:
Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 21, 2014
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PETNorbert Galldiks, Veronika Dunkl, Gabriele Stoffels, et al.
Neurology|September 29, 2020
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphomaSabine Seidel, Hendrik Pels, Sabine Schlömer, et al.
Pharmaceuticals (Basel, Switzerland)|March 6, 2021
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation StatusMatthias Schneider, Anna-Laura Potthoff, Bernd O Evert, et al.
Neurology|February 27, 2015
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphomaAgnieszka Korfel, Eckhard Thiel, Peter Martus, et al.
Journal of Neuro-Oncology|June 15, 2022
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUSJohannes Weller, Niklas Schäfer, Christina Schaub, et al.
Neuro-Oncology|March 2, 2023
Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclassesRichard Drexler, Jennifer Göttsche, Thomas Sauvigny, et al.
Neurosurgical Review|May 14, 2021
Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedomMajd Bahna, Muriel Heimann, Christian Bode, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PETJan-Michael Werner, Johannes Weller, Garry Ceccon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 10, 2025
Intraoperative radiotherapy for resectable brain metastases: a systematic review and meta-analysisCas Stefaan Dejonckheere, Matthias Schneider, Anna-Laura Potthoff, et al.
Pageof 25

Showing results (151-160 of 243) with videos related to

Sort By:
Pageof 25
Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 21, 2014
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PETNorbert Galldiks, Veronika Dunkl, Gabriele Stoffels, et al.
Neurology|September 29, 2020
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphomaSabine Seidel, Hendrik Pels, Sabine Schlömer, et al.
Pharmaceuticals (Basel, Switzerland)|March 6, 2021
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation StatusMatthias Schneider, Anna-Laura Potthoff, Bernd O Evert, et al.
Neurology|February 27, 2015
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphomaAgnieszka Korfel, Eckhard Thiel, Peter Martus, et al.
Journal of Neuro-Oncology|June 15, 2022
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUSJohannes Weller, Niklas Schäfer, Christina Schaub, et al.
Neuro-Oncology|March 2, 2023
Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclassesRichard Drexler, Jennifer Göttsche, Thomas Sauvigny, et al.
Neurosurgical Review|May 14, 2021
Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedomMajd Bahna, Muriel Heimann, Christian Bode, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PETJan-Michael Werner, Johannes Weller, Garry Ceccon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 10, 2025
Intraoperative radiotherapy for resectable brain metastases: a systematic review and meta-analysisCas Stefaan Dejonckheere, Matthias Schneider, Anna-Laura Potthoff, et al.
Pageof 25